US/UK/Canada

Share

Contacts

  • General Press Enquiries
    For general press enquiries please contact the AbbVie Corporate Communications team at UKMediaRelations@abbvie.com or call us on 01628 925200
    01628 925200
    https://twitter.com/abbvieuk

    • Quotes

    “AbbVie is incredibly proud to be recognised in the Best Workplaces™ list for the 8th year in a row. Participation in a Great Place to Work survey is extremely valuable to us, enabling our employees to share their views and shape our organisation on key areas of our culture, including development and recognition, employee engagement and wellbeing, and organisational leadership.”
    Henri Louw, HR Director at AbbVie UK
    Pick a time period -

    New SKYRIZI [® ][]▼ (risankizumab) 150 mg Presentation Pre-filled Pen and Pre-filled Syringe Approved by the Medicines and Healthcare Products Regulatory Agency (MHRA)

    · Risankizumab is now administered as one injection per dose, either by pre-filled pen or pre-filled syringe[1] · Approval based on results showing the new formulation of risankizumab 150 mg demonstrated bioequivalence to two injections of risankizumab 75 mg[1] MAIDENHEAD, UK, June 4, 2021 – AbbVie (NYSE: ABBV) today announced the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new risankizumab 150 mg presentation, to be administered by one injection per dose via pre-filled pen or pre-filled syringe every 12 weeks following an initiation dose at week 0 and

    New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ[®] ▼ (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

    · Long-term data from the Phase 3 SELECT-COMPARE trial show that continuous treatment with upadacitinib plus methotrexate (MTX) maintained rates of clinical remission and low disease activity through three years in adults with rheumatoid arthritis[1] · In a separate integrated safety analysis of upadacitinib, no new significant safety findings were observed up to 4.5 years in patients with rheumatoid arthritis[2] · Results from both presentations will be shared at the EULAR 2021 Virtual Congress · Upadacitinib is an oral, once-daily, selective and reversible JAK inhibitor approved

    The Lancet Publishes Results from Pivotal Global Phase 3 Programme Evaluating RINVOQ[®] (upadacitinib) ▼ in Atopic Dermatitis

    MAIDENHEAD, UK, May 24, 2021 – AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating RINVOQ[®] (upadacitinib) ▼ in adults and adolescents with moderate to severe atopic dermatitis who were candidates for systemic treatment. The results were published in two separate manuscripts as part of the May 22,[ ]2021 issue of The Lancet.  The publication of Measure Up 1 and Measure Up 2 shares efficacy and safety results of patients treated with upadacitinib (15 mg or 30

    SMC Accepts AbbVie’s RINVOQ [® ]▼ (upadacitinib) For Use in Adults with Active Psoriatic Arthritis

    · This decision means that upadacitinib will be available in Scotland for eligible patients with previously treated active psoriatic arthritis (PsA) [1] · Across pivotal clinical trial programmes, upadacitinib (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) with a safety profile consistent with that seen in rheumatoid arthritis (RA)[2,3,4] · Upadacitinib is now the first-ever, once-daily oral JAK approved for the treatment of PsA, ankylosing spondyloarthritis, and rheumatoid arthritis MAIDENHEAD, UK, May 10, 2021 –

    AbbVie is recognised as one of the 2021 UK’s Best Workplaces™

    Thursday, 29[th] April 2021 – Employees have spoken! AbbVie, a research-based global biopharmaceutical company, today announces it has achieved a 16[th] ranking on the 2021 UK’s Best Workplaces™list (in the Large category) published by Great Place to Work® UK today.Constantly striving to reach the best outcomes for patients, is just one of the reasons why employees are proud to work for AbbVie. AbbVie have sustained their position as a leading Pharmaceutical company within our category of the Best Workplaces™ list, with 84% of survey participants saying that ‘This is a Great Place to

    AbbVie report calls for much needed improvements to Shared Decision Making in the NHS

    Maidenhead, UK, 24[th] March, 2021 -- AbbVie, a research-based global biopharmaceutical company, has today launched a policy report looking at the role patients (and their families) should have in the decisions made about their medical care and treatment, known as Shared Decision Making (SDM).The report draws on the findings from AbbVie’s roundtable discussions, chaired by Lib Dem Peer Baroness Judith Jolly and with involvement from key patient advocacy groups, national health and professional bodies, and other parliamentarians to understand how COVID-19 has impacted the implementation of

    SMC Issues Positive Decision for Treatment with AbbVie’s RINVOQ[®]▼(upadacitinib) in Severe Active Rheumatoid Arthritis (RA)

    · Positive indication means upadacitinib will be available to those with previously treated severe active RA[1]* · SMC approval is based on data from pivotal Phase 3 SELECT clinical trial programme, in which upadacitinib demonstrated improved rates of clinical remission** compared to treatment with placebo; methotrexate (MTX) monotherapy; and adalimumab (TNF antagonist) plus MTX in patients with severe RA[2-6] · For the majority of people living with RA, remission is not currently achieved.[7] An estimated 44,000 people in the Scotland live with RA[8]The Scottish Medicines Consortium (

    European Commission Approves AbbVie’s RINVOQ [® ](Upadacitinib) ▼ for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

    · RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] · Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where upadacitinib met all primary and key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis[2-6] · Approvals underscore AbbVie’s longstanding commitment to deliver innovative medicines

    CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) ▼ for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis

    · Across pivotal clinical trial programmes, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis (RA)[1-4] · If approved, RINVOQ will be the first oral, selective and reversible JAK inhibitor approved in three rheumatologic conditions in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis · The European Commission decisions for both indications are anticipated in early 2021

    SMC Accepts Chemotherapy-free Combination Treatment VENCLYXTO[®] ▼ (venetoclax) Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia

    ·For the first time in Scotland, certain people with untreated chronic lymphocytic leukaemia (CLL) will have access to a chemotherapy-free, 12-month fixed-duration treatment option.[1] · Scottish Medicines Consortium (SMC) acceptance is based on data from the Phase III CLL14 trial, which showed patients treated with 1 year of treatment with venetoclax plus obinutuzumab had superior progression-free survival and sustained that benefit after stopping treatment, compared with those receiving a commonly used chemo-immunotherapy regimen of obinutuzumab and chlorambucil.[2] · CLL is the

    NICE gives green light for chemotherapy-free combination, Venclyxto® ▼(venetoclax) plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL)

    ·Positive recommendation for Venclyxto (venetoclax) means that all previously untreated patients with chronic lymphocytic leukaemia (CLL) will, for the first time, have a chemotherapy-free, fixed-duration treatment option[1 ] ·NICE approval is based on data from Phase III CLL14 trial, which showed that patients treated with 1 year of treatment with venetoclax plus obinutuzumab had superior progression-free survival and sustained that benefit after stopping treatment compared with those receiving a commonly used chemoimmunotherapy regimen of obinutuzumab and chlorambucil[2] · CLL

    NICE Issues Positive Final Appraisal Determination for AbbVie’s RINVOQ[®]▼(upadacitinib) in Severe Active Rheumatoid Arthritis (RA)

    · Positive recommendation means upadacitinib will be available to those with previously treated severe active RA[1]* · NICE approval is based on data from pivotal Phase 3 SELECT clinical trial programme, in which upadacitinib demonstrated improved rates of clinical remission** compared to treatment with placebo; methotrexate (MTX) monotherapy; and adalimumab plus MTX in patients with moderate to severe RA[2-6]  · An estimated 400,000 people in the UK live with rheumatoid arthritis[7 ]and for the majority remission is not achieved currently[8]Maidenhead, UK, Nov. 6[th], 2020 – The

    AbbVie UK Publishes 2019 Transparency Data; Supporting Collaboration of Medical Opinion Towards Advancing Patient Care and the Development of New Medicines

    Maidenhead, UK, 30 June 2020 – Each year AbbVie discloses individual and aggregated transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs) to the Association of the British Pharmaceutical Industry (ABPI). Due to the unprecedented demands on the NHS as a result of the COVID-19 pandemic, the ABPI provided guidance to companies to submit only their aggregated transfers of value data for 2019 for publication on its central platform, Disclosure UK, and to publish their disaggregated data on their company websites. AbbVie has adopted this guidance and our

    New VENCLYXTO®▼(venetoclax) Data Demonstrate Utility Across Acute Myeloid Leukaemia (AML) Patients and Chronic Lymphocytic Leukaemia (CLL)

    ·Phase III VIALE-A study showed a 34% reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared with azacitidine plus placebo[1] · Patients in the venetoclax arm showed improved median overall survival (14.7 months) versus azacitidine alone (9.6 months) and improved rate of composite complete remission (CR + CRi) (66.4%) versus those treated with azacitidine alone (28.3%)[1] · Notable data in CLL patients include Phase III results from the CLL14 trial[2] and Phase III sub-analysis from the MURANO

    New Long-term Data from RINVOQ® ▼(upadacitinib). Phase 3 Studies in Rheumatoid Arthritis Presented at Annual European E-Congress of Rheumatology (EULAR)

    · Long-term results from the SELECT-COMPARE and SELECT-MONOTHERAPY studies showed that upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively[1,2] · Results from SELECT-EARLY and SELECT-COMPARE showed upadacitinib inhibited structural joint damage in rheumatoid arthritis patients receiving upadacitinib as monotherapy or in combination with MTX at almost two years[3] · Upadacitinib’s safety profile was consistent across the pivotal Phase 3 programme, with no new safety signals identified[1-5] MAIDENHEAD, UK,

    AbbVie host shared decision making showcase in Parliament to highlight importance of patients being involved in decisions about their care

    MAIDENHEAD, UK, 10[th] March, 2020 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today hosted a Showcase on Shared Decision Making, which highlighted the importance of patients being involved in decisions made about their care. The showcase took place just over one year after the launch of the NHS Long Term Plan and Universal Personalised Care Plan which established ambitious targets to put shared decision making at the heart of patient care. The showcase provided a platform for patient groups, NHS Trusts, and healthcare providers to share their innovative

    RINVOQ® ▼(upadacitinib) Granted EU Marketing Authorisation for the Treatment of Eligible Adults with Moderate to Severe Active Rheumatoid Arthritis

    · Marketing authorisation supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis programme evaluating nearly 4,400 patients[1-5] · In five pivotal Phase 3 studies, upadacitinib met all primary and ranked secondary endpoints across a variety of adult patient populations with moderate to severe active rheumatoid arthritis[1-5] · Upadacitinib offered patients improved rates of clinical remission* or low disease activity** compared to treatment with placebo; methotrexate monotherapy; and adalimumab plus methotrexate [1-5] · An estimated 400,000 people in the UK are

    AbbVie Presents New Long-Term Data From VENCLYXTO®▼ (venetoclax) Chemotherapy-Free Combination Regimen in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    · Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with venetoclax plus rituximab (VenR) and higher rates of undetectable minimal residual disease (uMRD) compared to bendamustine plus rituximab(BR)1 · Sustained overall survival (OS) benefit was demonstrated with VenR over BR (with a hazard ratio of 0.41), despite 79% of patients in the BR arm who went on to receive a novel targeted treatment. Median OS was not reached for either treatment group1 · 68% of the 130 patients who completed the

    SKYRIZI™▼(risankizumab) Receives NICE Positive Technology Appraisal Guidance for the Treatment of Plaque Psoriasis in Adults

    MAIDENHEAD, UK, 21 August 2019 - AbbVie (NYSE: ABBV), a research-based biopharmaceutical company, announces that eligible patients in England and Wales with plaque psoriasis who have failed conventional systemic therapies will have access to SKYRIZI™▼(risankizumab) following the issuing by the National Institute for Health and Care Excellence (NICE) of the Technology Appraisal Guidance (TAG) recommending the treatment[1]. The TAG represents the completion of the final step of NICE assessment and follows a positive recommendation by NICE through its Fast Track Appraisal process, which has

    Results From SKYRIZI™ ▼ (risankizumab) Phase 3 Study in Moderate to Severe Plaque Psoriasis Published in The Lancet

    · In the IMMvent study, 72 percent and 84 percent of patients treated with SKYRIZI™ (risankizumab) achieved PASI 90 and sPGA 0/1, respectively, at week 16 [i] Maidenhead, UK, 24 July 2019 — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the publication of positive results from the pivotal Phase 3 IMMvent clinical study in The Lancet. The study evaluates the safety and efficacy of SKYRIZI™▼ (risankizumab) up to 44 weeks compared to adalimumab in adult patients with moderate to severe chronic plaque psoriasis.[1] Risankizumab met the co-primary

    AbbVie Appoints New General Manager in U.K.

    Maidenhead, UK, 19th July 2019 – AbbVie, a global biopharmaceutical company, today announced that Todd Manning has been named General Manager, AbbVie U.K. This change will be effective 1st September 2019. Todd moves to the UK from his current position within the company as General Manager, AbbVie Ireland. Elected to the Irish Pharmaceutical Healthcare Association (IPHA) strategy board in 2016 and to the Board of Directors in 2018, he has held the positions of Deputy Vice President and Chair of the Finance Committee. He also served on several working groups including Market Access and

    NICE Issues Positive Final Appraisal Document for SKYRIZI™▼(risankizumab) for the Treatment of Plaque Psoriasis in Adults

    – Positive NICE Final Appraisal Document (FAD) for SKYRIZI™ (risankizumab), a humanised immunoglobulin G1 (IgG1) monoclonal antibody, means that adult patients in England and Wales with plaque psoriasis, who have failed conventional systemic therapies, will have NHS access to treatment with high rate of skin clearance at 16 weeks that is maintained through to one year (52 weeks)[1] - Risankizumab has been reviewed by NICE through its Fast Track Appraisal process, meaning that NHS England/commissioners have committed to providing funding for risankizumab within 30 days of final guidance

    Results from Upadacitinib Phase 3 SELECT-COMPARE Study Published in Arthritis and Rheumatology

    · SELECT-COMPARE, the largest of the six studies in the robust SELECT programme, evaluates upadacitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate (MTX), and remain on a stable background of MTX[1] · Both primary endpoints of the study were met, including the proportion of patients achieving ACR20 response and clinical remission (DAS28-CRP<2.6) at week 12 for upadacitinib versus placebo[1] · No new safety signals were reported compared to previously reported Phase 3 studies[1-5] · Upadacitinib, an oral

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media